目的 在藏医理论体系中，西红花是“治一切肝病”的要药，本文通过网络药理学方法，探讨藏药西红花防治肝病的物质基础及作用机制。 方法 基于西红花成分的专属性、口服利用率、生物利用率及药理研究报道筛选用于网络药理学研究的成分。利用PharmMaper数据库对所选成分进行靶点预测，建立“成分-靶点”网络并开展网络分析；对预测靶点开展PPI互作网络分析，KEGG通路富集等生物功能注释；结合OMIM、Disgenet数据库获取肝病基因，建立“成分-靶点-疾病”网络。 结果 经过对西红花成分的筛选、分析得到19个西红花的化学成分，预测潜在靶点80个；其中PI3K-Akt、MAPK等12条通路与肝癌、肝纤维化、乙型肝炎、丙型肝炎、非酒精性脂肪肝等肝病相关度较高。通过对“成分-靶点”网络和“成分-靶点-疾病”网络的分析推测藏药西红花防治肝病的关键靶点为SRC和EGFR。 结论 初步明确藏药西红花在防治肝病的临床应用范围及可能的作用机制与关键靶点，为补充完善藏医药理论提高临床疗效提供了科学支撑。
Objective: To elucidate the mechanism of Crocus sativus L. (saffron) in the prevention and treatment of liver disease by network pharmacology and investigate the relationship between Sino-Tibetan medicine in the use of saffron. Methods: Using oral utilization, bioavailability and pharmacology studies as the limiting conditions, the components of saffron were screened, the related targets were predicted using PharmMaper server, and the "components-targets" network was established for the network analysis. OMIM and Disgenet databases were used to screen hepato-related genes and protein targets; the KEGG pathway was used to enrich the selected targets; the network of "components-targets-disease" was obtained by PPT analysis. Results: 19 components were screened and 80 potential targets were predicted. Molecular docking results showed that 12 pathways including PI3K-AKT, MAPK are highly hepato-related. Among them, SRC and EGFR are the key targets. Conclusion: The mechanism of the saffron in the prevention and treatment of liver disease was discussed. It will provide theoretical basis for the clinical application of Tibetan medicine in the future.